ADA and multiple sclerosis: It is not clear if the human origin of ofatumumab is the only reason for low levels of ADA in the multiple sclerosis indication, but levels of ADA detected for other human mAbs approved only for autoimmune indications range from <1% up to 61% (data not shown).